Neurology

Atogepant (Qulipta; AbbVie) is the first and only oral calcitonin gene-related peptide receptor antagonist to gain FDA approval for the prevention of episodic and chronic migraine.

The efficacy and tolerability of rizatriptan for acute migraine treatment has been well established.

Pharmacists are crucial in supporting patients with attention-deficit hyperactivity disorder as shortages of Adderall continue.

As more drugs gain coverage, decision-makers will need to more accurately diagnose Alzheimer disease, especially in the community setting.

The implementation of genetic testing for patients prescribed medications associated with progressive multifocal leukoencephalopathy is likely to improve safety outcomes.

Although attention-deficit/hyperactivity disorder (ADHD) is not as common in adults, it can still be present and bothersome, however, adults with ADHD may have learned to hide it a bit better than children.

Children in the LT-001 study treated after onset achieved or maintained additional milestones up to 7.5 years after 1-time intravenous infusion, Novartis says.

Strong interprofessional team helps ensure safe transitions and minimize adverse events, medication errors

Liquid formulations of dabrafenib plus trametinib were also approved, marking the first time a BRAF/MEK inhibitor has been developed in a formulation suitable for patients as young as 1 year of age.

Perceived stress and cognitive performance are independently associated. Stress can also increase the risk of worsening cognition.

Trofinetide is the first and only drug approved for the treatment of Rett syndrome.

Zavegepant is the only calcitonin gene-related peptide receptor antagonist nasal spray indicated for acute treatment of migraine in adults and can provide pain relief in 15 minutes.

Migraines are common yet misunderstood, therefore it is important that various treatment options be examined and offered to this patient population.

A patient’s neurological symptoms diminished when he discontinued a biosimilar and started various new treatments.

Investigators noted medication prescription disparities among patients with dementia despite factoring for age and sex.

Vitamin D may reduce the risk of dementia because it clears amyloid that accumulates in the brain.

Friedreich’s ataxia is a rare neuromuscular disease that affects approximately 5000 patients in the United States.

Zavegepant is the first calcitonin gene-related peptide receptor for migraines in development as an intranasal formulation studied in a phase 3 trial.

New research from Harvard Medical School could be a game changer for the management of headaches associated with anti-CGRP migraine therapy.

Austedo XR will be available in 3 extended-release tablet strengths, which provides an updated regimen that may result in a lower pill count for patients.

Students may be hesitant to discuss migraines, which can lead to absences, difficulties in personal life, financial burdens, and poor mental health.

Low cognitive functioning and cognitive decline have been linked to an increased risk of morbidity and mortality.

Pimavanserin is an atypical antipsychotic indicated for the treatment of Parkinson disease-associated hallucinations and delusions.

Patients with acute migraines should assess their condition before starting a treatment regimen.

Promising results for lecanemab's efficacy in patients with mild cognitive impairment or mild dementia associated with Alzheimer disease were accompanied by reports of adverse effects associated with treatment.

Researchers noted no significant changes in anxiety or depression between patients who were positive or negative for amyloid deposition.

The model can predict the chronological ages of cognitively normal participants with an average absolute error of 2.3 years, which is about 1 year more accurate than an existing model.

Analysis indicates that Acadia Pharmaceuticals Inc’s pimavanserin is the only FDA-approved medication for the treatment of delusions and hallucinations associated with PDP.

Lecanemab (Lequembi) approved to treat mild cognitive impairment or mild dementia associated with Alzheimer disease.

Indication can play a major role in pharmacists recommending brain health products.